Tap1 down-regulation in primary melanoma lesions: An independent marker of poor prognosis

International Journal of Cancer

Volumn 95, Issue 1, 2001, Pages 23-28

  Kamarashev, Jivko ^a   Ferrone, Soldano ^b   Seifert, Burkhardt ^c   Böni, Roland ^a   Nestle, Frank O ^a   Burg, Günter ^a   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; HLA ANTIGEN CLASS 1; PROTEASOME; PROTEIN LMP2; PROTEIN LMP7; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MELANOMA; METASTASIS; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID TRANSPORT SYSTEMS; ANTIBODIES, MONOCLONAL; ATP-BINDING CASSETTE TRANSPORTERS; BETA 2-MICROGLOBULIN; CYSTEINE ENDOPEPTIDASES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOWN-REGULATION; EXORIBONUCLEASES; FEMALE; FOLLOW-UP STUDIES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; MULTIENZYME COMPLEXES; NEOPLASM METASTASIS; PROGNOSIS; PROTEIN BIOSYNTHESIS; RECURRENCE; SACCHAROMYCES CEREVISIAE PROTEINS; TIME FACTORS; VIRAL MATRIX PROTEINS;

EID: 0035915772     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20010120)95:1<23::AID-IJC1004>3.0.CO;2-4     Document Type: Article

References (42)

1. Melanoma
2. HLA-DR antigen expression in primary melanomas of the skin
3. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: Association with disease progression
4. Direct evidence to support the immunosurveillance concept in a human regressive melanoma
5. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines
6. Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma
7. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens
8. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome
9. Proteasomes and antigen processing
10. Peptide antigen production by the proteasome: Complexity provides efficiency
11. Two putative subunits of a peptide pump encoded in the human major histocompatibility complex class II region
12. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
13. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma
14. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma
15. Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines
16. Development and characterization of mouse anti-human LMP2, LMP7, TAP1 and TAP2 monoclonal antibodies
17. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: Frequency and distribution
18. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: Frequency and distribution
19. Constant detection of surface and cytoplasmic immunoglobulin heavy and light chain expression in formalin-fixed and paraffin-embedded material
20. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis
21. Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex-encoded transporter gene
22. Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions
23. Immunosurveillance and melanoma
24. How does TAP associate with MHC class I molecules
25. Immunologic recognition of malignant melanoma by autologous T lymphocytes
26. Immune escape mechanisms in malignant melanoma
27. Combined interferon-alpha and interleukin-2 as adjuvant treatment for melanoma
28. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The eastern cooperative oncology group trial EST 1684
29. Role of proteasomes modified by interferon-gamma in antigen processing
30. + T cells in IRF-1-/- mice
31. IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma
32. Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin
33. Tumor escape from immune recognition: Lethal recurrent melanoma in a patient associated with down-regulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen
34. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions
35. Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis
36. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
37. T-cell recognition of human melanoma antigens
38. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity
39. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
40. Vaccination with dendritic cells pulsed with peptide or tumor lysates induces clinical remissions and immunological responses in melanoma patients
41. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
42. TAP expression provides a general method for improving the recognition of malignant cells in vivo